Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...
Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced publication of the findings from the randomized, phase III CALGB (Alliance ...
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...
Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...
The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...
Gender disparity in authorship of clinical trials leading to cancer drug approvals between 2008 and 2018: The glass ceiling of academic oncology. This is an ASCO Meeting Abstract from the 2022 ASCO ...
Kendra L. Sweet, MD, a SWOG investigator at Moffitt Cancer Center, reports results of the SWOG S1712 clinical trial at the ESH-iCMLf John Goldman Conference on CML in Prague, September 27th. The phase ...
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...
Tumor suppressor genes (TSG), treatment, and survival in de novo metastatic hormone-sensitive prostate cancer. Multivariate Cox proportional hazard model for PFS and OS. Bone Pain (yes vs No) 1.52, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback